These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 29848108)

  • 1. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
    Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
    J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
    Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
    Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
    Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
    Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
    Ailani J; Andrews JS; Rettiganti M; Nicholson RA
    J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
    Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
    J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
    Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
    J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
    Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
    BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
    Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
    Dodick DW; Doty EG; Aurora SK; Ruff DD; Stauffer VL; Jedynak J; Dong Y; Pearlman EM
    Cephalalgia; 2021 Mar; 41(3):340-352. PubMed ID: 33143451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
    Schwedt TJ; Myers Oakes TM; Martinez JM; Vargas BB; Pandey H; Pearlman EM; Richardson DR; Varnado OJ; Cobas Meyer M; Goadsby PJ
    Neurol Ther; 2024 Feb; 13(1):85-105. PubMed ID: 37948006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
    Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
    Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.